Close Menu

SAN DIEGO (GenomeWeb News) – Agilent Technologies today said that its board of directors has authorized the repurchase of up to $500 million of the firm's common stock during fiscal year 2013.

The company said that the new repurchase program replaces an existing stock repurchase program that had authorized the repurchase of shares to eliminate or reduce share dilution from equity programs.

Agilent finished its 2012 fiscal year on Oct. 31, 2012. It held $2.35 billion in cash and cash equivalents as of that date.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times Magazine examines gender discrimination at the Salk Institute.

Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.

A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.

In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.